Clinical Trials · NCT02281266
Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
- Phase
- Phase 4
- Recruitment status
- Unknown
- Sponsor
- Jia Fan
- Enrollment
- 360
- Start date
- Jan 2015
- Locations
- 1 site, China
- Primary endpoint
- Recurrence-free Survival